期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性肺血管扩张试验筛查在肺动脉高压中的应用 被引量：4

Application of acute pulmonary vasodilator testing in pulmonary arterial hypertension
原文传递
导出
摘要 钙拮抗剂(CCB)长程治疗仅对急性肺血管扩张试验(AVT)筛查阳性患者有效,因此AVT筛查对肺动脉高压患者的治疗策略具有关键作用,本文综述AVT筛查在肺动脉高压诊治中的应用。 Long-term treatment with calcium channel blocker（CCB） is correlated to acute pulmonary vasodilator testing（AVT）.Therefore,it could be a key indicator to make treatment strategy for pulmonary arterial hypertension.This review summarizes the application of AVT in diagnosis and treatment of pulmonary arterial hypertension.
作者 张宏达 邱梅红 荆志成
机构地区 同济大学附属上海市肺科医院心肺循环中心 吉林大学第一医院心血管中心 中国医学科学院北京协和医学院国家心血管病中心阜外心血管病医院心血管疾病国家重点实验室
出处 《世界临床药物》 CAS 2013年第5期271-274,279,共5页 World Clinical Drug
关键词 肺动脉高压 急性肺血管扩张试验 钙拮抗剂 pulmonary arterial hypertension acute pulmonary vasodilator testing calcium channel blocker
分类号 R544.16 [医药卫生—心血管疾病] R974 [医药卫生—药品]
  • 相关文献

参考文献25

  • 1Sitbon 0, Humbert M,Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension[J]. Circulation, 2005, 111 (23) : 3105-3111.
  • 2Yamaki S, Wagenvoort CA. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients[J]. Br HeartJ, 1985, 54 (4): 428-434.
  • 3Rosenzweig EB, MorseJH, KnowlesJA, et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension[J].J Heart Lung Transplant, 2008, 27 (6): 668-674.
  • 4Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines[J]. Chest, 2007, 131 (6): 1917-1928.
  • 5Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension[J] . Eur HeartJ, 2010, 31 (15) : 1898-1907.
  • 6Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy[J]. Circulation, 1987,76 (1): 135-141.
  • 7Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertensionlJ J.N EnglJ Med, 1992,327 (2): 76-81.
  • 8Sitbon 0, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclinlJ]. AmJ Respir Crit Care Med, 1995, 151 (2): 384-389.
  • 9Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS), endorsed by the international society of heart and lung transplantation (ISHLT)[J]. Eur HeartJ, 2009, 30 (20): 2493-2537.
  • 10Barst RJ, Agnoletti G, Fraisse A, et al. Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension[J]. Pediatr Cardiol, 2010, 31 (5) : 598-606.

同被引文献32

  • 1荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志（电子版）,2011,3(2):62-81. 被引量：117
  • 2肖亦敏,肖明第,施盛,毛建强,周黎瑾.动脉导管未闭合并重度肺动脉高压介入与手术治疗比较[J].中国介入心脏病学杂志,2007,15(4):218-221. 被引量：7
  • 3Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance inadultcongenitalheartdisease: comparative severity, correlates, and prognostic implication. Circulation, 2005, 112:828-835.
  • 4Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease:a description of six grades of structural changes in the pulmonary arteries with special reference to congenital heart defect. Circulation, 1985, 18:533-547.
  • 5Reqitz-Zaqrosek V, Blomstrom Lundqvist C, Borqhi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnanlines on the management of cardiovascular Diseases during Pregnancy of the European Society of Cardiology(ESC). Eur Heart J, 2011, 32:3147-3197.
  • 6Regita Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnanlines on the management of cardiovascular Diseases during Pregnancy of the European Society of Cardiology(ESC). Eur Heart J, 2011, 32:3147-3197.
  • 7朱鲜阳,秦永文,张玉顺,等.常见先天性心脏病介入治疗中国专家共识.心血管疾病防治指南和共识,2009:1-103.
  • 8Gupta V, Tonelli AR, Krasuski RA. Congenital heart disease and pulmonary hypertension. Heart Fail Clin, 2012, 8:427-445.
  • 9Beghetti M, Gali N, Bonnet D. Can "inoperable" congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality?. Congenit Heart Dis, 2012, 7:3-11.
  • 10Gali6 N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in pat/ents with Eisenmenger syndrome:a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 2006, 114:48-54.

引证文献4

二级引证文献17

世界临床药物
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部